Association studies of serum prostate-specific antigen levels and the genetic polymorphisms at the androgen receptor and prostate-specific antigen genes

Cancer Epidemiology Biomarkers and Prevention

Volumn 11, Issue 7, 2002, Pages 664-669

  Xu, Jianfeng ^a   Meyers, Deborah A ^a   Sterling, David A ^a,b   Zheng, Siqun L ^c   Catalona, William J ^d   Cramer, Scott D ^a   Bleecker, Eugene R ^a   Ohar, Jill ^a  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

^b SAINT LOUIS UNIVERSITY   (United States)

^c SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN RECEPTOR; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; BLOOD LEVEL; CONTROLLED STUDY; EXON; GENE LINKAGE DISEQUILIBRIUM; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; MALE; PRIORITY JOURNAL; PROSTATE CANCER; SENSITIVITY AND SPECIFICITY; SINGLE STRAND CONFORMATION POLYMORPHISM; STATISTICAL ANALYSIS;

ADULT; AGED; AGED, 80 AND OVER; ANALYSIS OF VARIANCE; BASE SEQUENCE; COHORT STUDIES; GENOTYPE; HUMANS; MALE; MIDDLE AGED; MOLECULAR SEQUENCE DATA; POLYMERASE CHAIN REACTION; POLYMORPHISM, GENETIC; PROBABILITY; PROSPECTIVE STUDIES; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL;

EID: 0036313591     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Prostate-specific antigen velocity and repeated measures of prostate-specific antigen
2. Cancer surveillance series: Interpreting trends in prostate cancer- Part I: Evidence of the effects of screening in recent prostate cancer incidence, mortality, and survival rates
3. Prostate cancer detection in men with serum PSA concentrations of 2.6 to 4.0 ng/mL and benign prostate examination. Enhancement of specificity with free PSA measurements
4. Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: A prospective multicenter clinical trial
5. Characteristics of screening detected prostate cancer in men 50 to 66 years old with 3 to 4 ng./ml. Prostate specific antigen
6. Optimal predictors of prostate cancer on repeat prostate biopsy: A prospective study of 1, 051 men
7. Extended field prostate biopsy enhances cancer detection
8. The incidence of prostate cancer in a screening population with a serum prostate specific antigen between 2.5 and 4.0 ng/ml: Relation to biopsy strategy
9. Age- and race-specific reference ranges for prostate-specific antigen from a large community-based study
10. Human prostate-specific antigen (APS) is a member of the glandular kallikrein gene family at 19q13
11. Characterization of the prostate-specific antigen gene: A novel human kallikrein-like gene
12. Prostate-specific antigen expression is regulated by an upstream enhancer
13. Two androgen response regions cooperate in steroid hormone regulated activity of the prostate-specific antigen promoter
14. Genetic determinants of serum prostate-specific antigen levels in healthy men from a multiethnic cohort
15. Susceptibility to prostate cancer: Interaction between genotypes at the androgen receptor and prostate-specific antigen loci
16. Exact tests for association between alleles at arbitrary numbers of loci
17. Lowering PSA cutoffs to enhance detection of curable prostate cancer
18. A PSA threshold of 4.0 ng/mL for early detection of prostate cancer: The only rational approach for men 50 years old and older
19. Serum prostate-specific antigen for prostate cancer early detection: Total, free, age-stratified, or complexed?
20. Relative sensitivity and specificity of serum prostate specific antigen (PSA) level compared with age-referenced PSA. PSA density and PSA change: Data from the American Cancer Society National Prostate Cancer Detection Project
21. Age- and race-specific reference ranges for prostate-specific antigen from a large community-based study
22. Estimation of prostatic growth using serial prostate specific antigen measurements in men with and without prostate disease
23. Prostate specific antigen and prostate gland volume: Correlation and clinical application
24. A complex between PSA and a antichymotrypsin is the major form of prostate specific antigen in serum of patients with prostatic cancer: Assay of the complex improves clinical sensitivity for cancer
25. Novel polymorphisms in prostate specific antigen gene and its association with prostate cancer